CellCentric to present inobrodib Phase I multiple myeloma efficacy data
04 Nov 2022 //
PRNEWSWIRE
CellCentric Strengthens Leadership Team
06 Apr 2022 //
PRNEWSWIRE
CellCentric secures investment from ASC`s venture capital fund for inobrodib
26 Jan 2022 //
PRNEWSWIRE